Skip to main content

Table 2 Change in symptoms, therapy and visual analogue scale (VAS) ratings between T0 and T1 (n = 35)

From: Diisocyanate-induced asthma in Switzerland: long-term course and patients’ self-assessment after a 12-year follow-up

 

T0

T1

p-value

Upper airway symptoms

28 (80%)

9 (26%)

<0.001

Asthma symptoms

34 (97%)

20 (57%)

<0.001

Use of asthma medication*

31 (91%)

19 (56%)

0.002

Short acting beta2 agonists

19 (56%)

13 (38%)

0.18

Long acting beta2 agonists

10 (29%)

10 (29%)

1.0

Inhalable corticosteroids

26 (76%)

10 (29%)

<0.001

Smokers

10 (29 %)

14 (40%)

0.05

VAS (cm) health status

1.2 (2.9)

8.0 (4.0)

<0.001

VAS (cm) overall satisfaction

2.1 (6.1)

8.3 (3.4)

<0.001

  1. Legend: Upper airway symptoms (conjunctivitis, rhinitis, hoarseness, pharyngeal irritant sensations); asthma symptoms (irritation, wheezing, chronic cough, chest tightness and dyspnoea); VAS = visual analogue scale. Data is presented as mean ± SD, median and interquartile range (IQR) or number (%).
  2. *n = 34.
Back to article page

Journal of Occupational Medicine and Toxicology

ISSN: 1745-6673